兒童抗癲癇藥物市場：依藥物類型、給藥途徑、分銷管道和地區分類。

預計到 2026 年，兒童抗癲癇藥物市場規模將達到 15.994 億美元，到 2033 年將達到 27.768 億美元。預計從 2026 年到 2033 年，該市場將以 8.2% 的複合年成長率成長。

癲癇是一種常見的神經系統疾病，影響著世界各地各個年齡層的人群。然而，癲癇在兒童中更為常見，約70%的癲癇病例在成年之前確診。抗癲癇藥物在控制癲癇發作和提高癲癇兒童的生活品質方面發揮著至關重要的作用。這些藥物透過控制大腦中異常的神經細胞放電和同步性來預防癲癇發作。近年來，大量的研究促成了新一代抗癲癇藥物的研發和批准，這些藥物比傳統的兒童藥物更有效，副作用更少。這顯著提高了癲癇兒童的用藥依從性和治療效果。兒童癲癇的病因包括創傷、分娩併發症或遺傳性疾病。由腦膜炎等腦部感染疾病引起的癲癇稱為“症狀性癲癇”，而遺傳相關疾病引起的癲癇則稱為“特發性癲癇”。

市場動態

全球兒童抗癲癇藥物市場成長的主要驅動力是兒童癲癇盛行率的不斷上升。根據世界衛生組織（WHO）統計，全球約有1%的兒童患有癲癇。此外，醫療保健支出增加、人們對癲癇治療的認知不斷提高以及新型抗癲癇藥物的問世等因素也推動了市場成長。然而，該市場也面臨一些限制因素，例如藥物研發高成本以及兒童藥物核准的嚴格監管。此外，抗癲癇藥物對兒童發育中的神經系統可能產生的副作用也是一大挑戰。另一方面，對疾病修正治療的持續研究以及個人化抗癲癇藥物治療的開發，將在未來為市場相關人員帶來巨大的機會。

本研究的主要特點：

• 這項研究揭示了各個細分市場的潛在成長機會，並為該市場說明了一個有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數介紹了全球兒童抗癲癇藥物市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
• 本次調查涵蓋的主要公司包括賽諾菲、Eisai、輝瑞公司、UCB SA、Sunovion Pharmaceuticals、雅培製藥、Jazz Pharmaceuticals、Ovid Therapeutics、SK Biopharmaceuticals、Alexa Pharmaceuticals、大正控股製藥株式會社、Marinus Pharmaceuticals、Bapen Pharmaceuticals、大正控股製藥株式會社、Marinus Pharmaceuticals、 氙氣 Pharmaceuticals、Honc​​買公司和工業企業有限公司。
• 本報告提供的見解將有助於各公司的行銷負責人和經營團隊就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
• 這份《全球兒童抗癲癇藥物市場報告》旨在為該行業的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用全球兒童抗癲癇藥物市場分析中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
    • 神經系統疾病發生率增加
    • 研發活動活性化
  • 抑制因子
    • 監管機構的產品回收數量增加
    • 抗癲癇藥物的副作用
  • 市場機遇
    • 尚未開發的新興市場
    • 對標靶治療的需求日益成長
• 影響分析
• 監管指南
• 產品發布
• 主要進展
• PEST分析
• 波特的分析
• 監管趨勢
• 併購
• 製造商利潤
• 各國醫療保健成本

第4章 全球兒童抗癲癇藥物市場：依藥物類型分類，2021-2033年

• 概述
• 第一代抗癲癇藥物
• 第二代抗癲癇藥物
• 第三代抗癲癇藥物

第5章 全球兒童抗癲癇藥物市場：依給藥途徑分類，2021-2033年

• 概述
• 口服
• 注射藥物
• 其他（鼻噴劑等）

第6章 全球兒童抗癲癇藥物市場：依通路分類，2021-2033年

• 概述
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球兒童抗癲癇藥物市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第8章 競爭情勢

• Sanofi
• Eisai Co., Ltd.
• Pfizer Inc.
  • Company Highlight
• UCB SA
  • Company Highlight
• Sunovion Pharmaceuticals Inc.
• Abbott
• Jazz Pharmaceuticals plc
• Ovid Therapeutics Inc.
• SK BIOPHARMACEUTICALS
• Alexza Pharmaceuticals, Inc.
• Taisho Pharmaceutical Holdings Co., Ltd.
• Marinus Pharmaceuticals, Inc.
• Xenon Pharmaceuticals Inc.
• Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.

第9章

• 調查方法
• 關於本公司

Anti-Epileptic Drugs for Pediatrics Market is estimated to be valued at USD 1,599.4 Mn in 2026 and is expected to reach USD 2,776.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033.

Epilepsy is a common neurological disorder that affects people of all ages globally. However, it is more prevalent in children as almost 70% of epilepsy cases are diagnosed before reaching adulthood. Anti-epileptic drugs play a crucial role in managing seizures and improving quality of life for pediatric patients suffering from epilepsy. These medications work by controlling abnormal neuronal firing and synchrony in the brain to prevent seizures. In recent years, extensive research has led to the development and approval of newer generation anti-epileptic drugs that are more effective and have less side effects than the earlier drugs for pediatric use. This has positively impacted medication adherence and treatment outcomes for children with epilepsy. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while a genetics related condition is called idiopathic epilepsy.

Market Dynamics

The global anti-epileptic drugs for pediatrics market is driven by the growing prevalence of epilepsy among children. According to the World Health Organization (WHO), epilepsy affects around 1% of children worldwide. Besides this, factors such as increasing healthcare expenditures, rising awareness about epilepsy treatment, and introduction of newer anti-epileptic drugs are fueling the market growth. However, the market faces certain restraints such as high costs associated with drug development and stringent regulations for the approval of pediatric drugs. Moreover, adverse effects of anti-epileptic drugs on developing neurological system of children poses challenges. On the positive side, ongoing research on disease modifying therapies and development of personalized anti-epileptic drug regimens present notable opportunities for market players in the future.

Key features of the study:

• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anti-epileptic drugs for pediatrics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as part of this study include Sanofi, Eisai Co., Ltd., Pfizer Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Abbott, Jazz Pharmaceuticals plc, Ovid Therapeutics Inc., SK BIOPHARMACEUTICALS, Alexza Pharmaceuticals, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Marinus Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., H. Lundbeck A/S, and Teva Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics
• The global anti-epileptic drugs for pediatrics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs for pediatrics market

Detailed Segmentation:

• Global Anti-Epileptic Drugs for Pediatrics Market, Drug Type (Revenue, USD Mn, 2021 - 2033)
• First generation anti-epileptic drugs
• Second generation anti-epileptic drugs
• Third generation anti-epileptic drugs
• Global Anti-Epileptic Drugs for Pediatrics Market, Route of Administration:
• Oral
• Injectable
• Others (Nasal, etc.)
• Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles
• Sanofi
• Eisai Co., Ltd.
• Pfizer Inc.
• UCB S.A.
• Sunovion Pharmaceuticals Inc.
• Abbott
• Jazz Pharmaceuticals plc
• Ovid Therapeutics Inc.
• SK BIOPHARMACEUTICALS
• Alexza Pharmaceuticals, Inc.
• Taisho Pharmaceutical Holdings Co., Ltd.
• Xenon Pharmaceuticals Inc.
• Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trend Analysis

• Market Dynamics
  • Drivers
    • Increasing incidence of neurological disorders
    • Increasing research and development activities
  • Restraints
    • Increasing product recalls by regulatory authorities
    • Side effects of anti-epileptic drugs
  • Market Opportunities
    • Untapped emerging markets
    • The rising demand for targeted therapy
• Impact Analysis
• Regulatory Guidelines
• Product Launches
• Key Development
• PEST Analysis
• PORTER's Analysis
• Regulatory Scenario
• Mergers and Acquisitions
• Manufacturer Revenue
• Healthcare Spending by Country

4. Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, 2021 - 2033, (US$ Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• First generation anti-epileptic drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
• Second generation anti-epileptic drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
• Third generation anti-epileptic drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)

5. Global Anti-Epileptic Drugs for Pediatrics Market, By Route of Administration, 2021 - 2033, (US$ Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
• Others (Nasal, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)

6. Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)

7. Global Anti-Epileptic Drugs for Pediatrics Market, By Region, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021-2033, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eisai Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlight
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• UCB S.A.
  • Company Highlight
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sunovion Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Abbott
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Jazz Pharmaceuticals plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Ovid Therapeutics Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• SK BIOPHARMACEUTICALS
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Alexza Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Taisho Pharmaceutical Holdings Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Marinus Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Xenon Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lundbeck A/S
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us